chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Injection site a little warm; injection site was hard; Injection site itchy; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (Injection site a little warm), VACCINATION SITE INDURATION (injection site was hard) and VACCINATION SITE PRURITUS (Injection site itchy) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Jan-2021, the patient experienced VACCINATION SITE WARMTH (Injection site a little warm), VACCINATION SITE INDURATION (injection site was hard) and VACCINATION SITE PRURITUS (Injection site itchy). At the time of the report, VACCINATION SITE WARMTH (Injection site a little warm), VACCINATION SITE INDURATION (injection site was hard) and VACCINATION SITE PRURITUS (Injection site itchy) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       Laboratory details was not provided. No treatment information was provided.   Based on the current available information and temporal association between the use of the product and the start date of the events a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event,s a causal relationship cannot be excluded.
Patient called in to report that she had severe left arm pain. Stated that she went to the Emergency Room due to the pain and was told that she had fluid in the subcromial space in left shoulder (thought to be the vaccine). She states she is a retired nurse and thought that the nurse giving the vaccine gave the injection too high. She stated she was to have a MRI on 3/29/2021 but have not heard back from her with results. She stated she is also to see an Infectious Disease Physician to consult on if her vaccine is effective or she needs another vaccine. Patient did not give names of physicians to this nurse.
My eye was infected and started to swell up to the point that I could barely see. The doctor at the urgent care believes it to be a stye and it lasted for about a month with medications. I remember after getting my second covid shot, I went to class and took an exam and in the middle of it my left eye started itching/stinging and the next morning I woke up to a swollen eye.
It started with an intense itch on my right wrist, followed by lesions on the skin which spread quickly.  By day two, I had patches of red, scaly, itchy, bumps.  It spread to my fore-arm, then my other arm, and finally patches appeared on my chest and face.  On my face, it's like sandpaper and thick skin, but no itch.  I called my Dr. on day two, but they didn't think it was the vaccine, and said I should call the health dept.  I did, and they said to call the Doctor.  I decided to wait it out over the weekend, treating the itch with vinegar, and taking some Claritin.  Now (Day 5), the lesions are going away, and nothing itches, but I do still have rough, bumpy, and patchy red lesions.  Hopefully these also go away.  I did finally have two good nights sleep!
Muscle cramps, fever, nausea,  chills,  headache , Pain in armpit  Treated with Tylenol, ibuprofen , and mucinex cold and flu
mom called @ 455PM stating pt had cried cont since recv vax 1130AM today;pt recv APAP a/coming to clinic;mom stated pt slept about 1hr & cried constantly since working;given APAP q 3hr & had no relief;has put warm wash cloth on legs to help
Information has been received from a patient who was vaccinated with MMR II (route and site not reported). The patient had a previous experience with MMR II. No further information is available.
Localized itching, erythema, and swelling about 2 days after injection. Improved with BENADRYL administration,  no pain/tenderness.
puffiness of eyes, especially left eye.  Also bag and dark circle under left eye. Eye balls feel sore
Pregnant; This spontaneous prospective pregnancy case was reported by a patient and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Pregnant) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. Last menstrual period and estimated date of delivery were not provided. On an unknown date, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Pregnant). At the time of the report, MATERNAL EXPOSURE DURING PREGNANCY (Pregnant) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.   No treatment information was provided.
15 minutes p/vax recvd, pt began high pitched screaming for 3 hrs or more; also ran fever mom forgot what temp was @ time of rxn;
Information has been received from a pharmacist concerning multiple unspecified patients of unknown age and gender. The patients' medical history and concurrent condition were not reported.   Concomitant therapy included sterile diluent (manufacturer unknown) used to reconstitute vaccine (Lot# and expiration unknown). On multiple unknown dates of August 2017 (reported as over the past two weeks), the patients might have received VARIVAX (dose, route, lot# and expiry unspecified) rather than receiving ZOSTAVAX (lot# N003697, expiry expiration date: 13-MAR-2018; dose and route unspecified) (wrong vaccine administered). No adverse effects reported.
Received influenza and pneumococcal vaccine in right deltoid, separated by 2" according to nurse, on 12/01/00. Pt complained of inability to use right arm due to pain within 4 hours of receiving vaccines. Seen by her doctor on 12/4/00. Treated with Medrol dose pack. Pt improved but still has pain. Has been seen by orthopedic doctors who told her if a nerve was affected it would take 6-8 weeks for improvement.
Rash started on face and spread to over 70 different areas of body.  Continues to spread two weeks after vaccine.  Skin is itchy, hot to touch and burning sensation.  First treatment was Methylprednisolone dose pack for 6 days, Triamcinolone Acetonide Cream USP 0.5%, Benadryl oral.  No improvement.  Second treatment Prednisone 20MG for 5 days, Triamcinolone Acetonide Cream USP 0.5%, Benadryl oral.  Still no improvement 14 days after 2nd vaccine.
Varicella was given IM on 8/11/16; MMR and Polio were given IM on 8/18/16 - too early. Parents have been informed.
Information has been received from a physician concerning a female patient who was vaccinated with the first and only dose of GARDASIL when she was mildly ill.  After the vaccination, the patient got sicker.  She was determined to have "Mono" and developed shingles.  The patient eventually recovered.  The patient had seen the physician for medical attention.  Additional information has been requested.
8/25/10 pc from pt. (2 days after injection) c/o itching and redness at site of injection. 8/26/10 OV PHN observed red circular area around site of injection with induration (approx 75mm) Pt still c/o itching. 8/30 p/c to pt who was seen by PMD - AB TX and BENADRYL. Pt states symptoms better. Ab Tx: Sulfameth/TMT DS started 8/27/10.
Received flu vaccine 10/25/06. Noted increased shortness of breath, cough for over a week prior to receiving vaccine, but more acute 10/27/2006. Pneumonia, on vent, small pneumo, GI bleed. H&P HX of weakness, COPD. MD indicates that a flu vaccince administered 3 days prior to admission and then developed generalized symptoms of SOB, cough and malaise one day prior to admission is likely coincidental.  On ventilator, trached. DC Summary received for DOS 10/28-12/5/06- MRSA positive sputum DC DX: respiratory failure bilateral pneumonitis known left pneumothorax massive GI bleeding anemia secondary to blood loss malnutrition.
Positive for COVID-19 after first shot of the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Positive for COVID-19 after first shot of the vaccine) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event. Concomitant products included SIMVASTATIN, blood pressure medicine and CALCIUM CARBONATE, COLECALCIFEROL (VITAMIN D 2000) for an unknown indication.    On 13-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 (Positive for COVID-19 after first shot of the vaccine). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) at an unspecified dose and frequency. At the time of the report, COVID-19 (Positive for COVID-19 after first shot of the vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
This spontaneous report as received from a licensed practical nurse (also reported as registered nurse) refers to an unknown number of patients of unknown age and gender. Since 02-JAN-2015, an unknown number of doses of VAQTA (dose, route, anatomical location, lot # and expiration date were not reported), which underwent supported temperature excursions, have been administered to an unknown number of patients. No adverse effect reported. This is the one of several reports from the same reporter source. Additional information has been requested.
Patient Given Heplisav-B Intravenously; Partial Dose of Heplisav-B Administered; Decreased Blood Pressure with Treatment; Initial Report Received 11-Sep-2019  A pharmacist reported that a 26-year-old male dialysis patient (unknown race) received a "partial dose" of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization intravenously.    Relevant medical history and concomitant medications were reported as unknown.    On 11-Sep-2019, a pharmacist reported via phone that the patient received a "partial dose" of HEPLISAV-B (lot # L9539, expiration date: Dec 2021, and NDC # unknown) intravenously on this date. A physician was present for the phone call report. The physician telephoned the licensed vocational nurse (LVN), who joined the call with the physician and pharmacist. The LVN stated that the patient had not had any adverse reactions or symptoms of distress. The LVN also stated that the patient arrived at their facility for dialysis with elevated blood pressure. The blood pressure was monitored after the intravenous administration of HEPLISAV-B and it was at 173/96 while on treatment and that this was a normal pressure for him before dialysis. Clonidine was administered for the elevated pressure. At the time of this report, his blood pressure was decreasing. The physician and LVN reported that they would like to be contacted if further information was needed. No further information was provided.   At the time of the report, the LVN noted that the patient had not had any adverse reactions or distress.  The reporter did not provide a serious assessment for the event.   Company comment: The company assessed the events of incorrect route of product administration, incorrect dose administered by product and blood pressure management as non-serious. The events of incorrect route of product administration, incorrect dose administered by product and blood pressure management are unlisted per HEPLISAV-B USPI.; Sender's Comments: The company assessed the events of incorrect route of product administration, incorrect dose administered by product and blood pressure management as non-serious. The events of incorrect route of product administration, incorrect dose administered by product and blood pressure management are unlisted per HEPLISAV-B USPI and IB.
patient was hospitalized for COVID after having 2 shots of moderna on 2/2/2021 and 3/2/2021 No booster was given.  Of note: pt on mtx for RA
Information has been received from a medical assistant concerning a 69 year old female with allergies to epinephrine, sulfa and influenza vaccine who on 06-DEC-2007 was vaccinated (route and site not reported) with a dose of pneumococcal 23v polysaccharide vaccine (lot# 657626/1084U). Post vaccination (date not reported), the patient developed a swollen, hot and heavy arm. The patient went to the physician's office and received unspecified medical attention. No further information available. Additional information has been requested.
Developed a lump in left axilla(lymph node?) about golf ball sized. Lasted about 24 hours before began to resolve. Over next 48 hours resolved completely. Extreme discomfort!
W/in 1 hrs pt acted lifeless lt leg very swollen & hot; very high fever, sz approx 8 hrs p/vax mom says pt gave fever meds every 4 hrs;
Symptoms started at 1900 on 1/20. Headache, rigors, fever, malaise, body aches, nausea. Vomited on the morning of 1/21 at 0400. Symptoms persisted (except vomiting) until 1800 on 1/21/21.
Left arm is red, warm, little bumpy. It is also painful to touch. Dr feels the reaction was to the PENTACEL (DTaP, Hib, Polio).
3/22 Itchy, rash and lump appeared on right deltoid at injection site today. 3/23 raised red lump approx 3x4 cm-itchy, warm to touch. Benadryl cream, Advil. 3/25 much better on phone follow-up. 3/27 1cm lump, faded light red 2 cm area. No pain. Unaware of its presence.
1st dose: Headache, flu like symptoms and cramps; 1st dose: Headache, flu like symptoms and cramps; 1st dose: Headache, flu like symptoms and cramps; 10-15 days before 2nd shot, which was around 30Apr2021. The only thing that came back a little low was Testosterone; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 44-year-old male patient received BNT162b2 (BNT162B2), on 24Apr2021 as dose 1, single (Lot number: EW0161) at the age of 44 years, in left deltoid for COVID-19 immunization. The patient's relevant medical history included: "Other Conditions: No" (unspecified if ongoing), notes: Other Conditions: No. There were no concomitant medications. The following information was reported: BLOOD TESTOSTERONE DECREASED (non-serious) with onset 2021, outcome "unknown", described as "10-15 days before 2nd shot, which was around 30Apr2021. The only thing that came back a little low was Testosterone"; HEADACHE (non-serious), INFLUENZA LIKE ILLNESS (non-serious), MUSCLE SPASMS (non-serious), outcome "recovering" and all described as "1st dose: Headache, flu like symptoms and cramps". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: Patient received dose 1 in left shoulder. Prior Vaccinations (within 4 weeks) was none. Family Medical History Relevant to Adverse Events (AEs) was none. There were no any other products.The day of the 1st one. He got headache, flu and all that stuff and the cramps and that went away. He had a blood panel done and they said everything on blood panel, that was normal what they tested for. Drew 17 vials of blood drawn. 10-15 days before 2nd shot, which was around 30Apr2021. The only thing that came back a little low was Testosterone and they said really not even low. The normal was 100 and his was like on a scale of 90-120, he was like 95 or 90. He got the blood draw because he had been sick and never was sick before this and turned his life upside down with work and life.
1st dose Bexsero, 2nd dose was accidentally given Trumenba; This case was reported by a other health professional via call center representative and described the occurrence of interchange of vaccine products in a 18-year-old female patient who received Men B NVS (Bexsero) for prophylaxis.   Co-suspect products included meningococcal B recom vaccine + aloh + omv pre-filled syringe device (Bexsero Pre-Filled Syringe Device) injection syringe for prophylaxis and MENINGOCOCCAL B VACCINE (TRUMENBA) for prophylaxis.   Concomitant products included meningococcal B vaccine (Bexsero).   On an unknown date, the patient received the 2nd dose of Bexsero and Bexsero Pre-Filled Syringe Device. On 6th June 2022, the patient received TRUMENBA. On 6th June 2022, unknown after receiving Bexsero and Bexsero Pre-Filled Syringe Device, the patient experienced interchange of vaccine products. On an unknown date, the outcome of the interchange of vaccine products was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 08-JUN-2022 Reporter's Comment: The reporter was a clinic manager. The patient received her 1st dose of Bexsero and instead of getting a 2nd dose of Bexsero, she was accidentally given a dose of Trumenba. The reporter consented to follow up via email. Additional Supportive Information: The patient received her 1st dose of Bexsero and instead of getting a 2nd dose of Bexsero she was accidentally given a dose of Trumenba, which led to interchange of vaccine products.
the happy unexpected improvement; Fatigue; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP).  An 81-year-old female patient received BNT162b2 (BNT162B2), on 07Jan2021 as dose 1, single (Lot number: EL3246) at the age of 81 years for covid-19 immunisation. The patient's relevant medical history included: "vascular dementia alzheimers and parkinsons" (unspecified if ongoing); "vascular dementia alzheimers and parkinsons" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: FATIGUE (non-serious) with onset 2021, outcome "unknown"; THERAPEUTIC RESPONSE UNEXPECTED (non-serious) with onset 2021, outcome "unknown", described as "the happy unexpected improvement".  Additional information: This is not an adverse negative reaction but rather a positive side effect. At both initial vaccines my mother experienced a (Illegible word) cognitive improvement. More alert and responsive as if to suggest an arresting of disease process. She has vascular dementia alzheimers and parkinsons. Both of which degrade overall awareness and interactive responsiveness. Beyond a pronounced general fatigue which is the understood effect of any vaccine on the body, the happy unexpected improvement which seems to occurred with any revaccination of Pfizer COVID vaccine. Caller report for the record that research may result. One or more of the chemicals or chemistry of this product could prove useful in the fight of both alzheimers and parkinsons.
Had shot on 2/9, woke up 2/10 very sore shoulder..couldn't sleep on it.  Feeling nauseous...temp varied from 99.3 to 100.2 vomited then felt better, but still had temperature
PENTACEL and PCV13 at 1400 1/21/16 fever onset 0530 1/22/16 called 911. Take to ER. Clinic notes, ER Report and RSV result included. Febrile seizure.
At 7 pm following an after school clinic patient experienced shortness of breath, nausea, vomiting, was given an EPIPEN and transported to hospital.
1.  Light headedness.  Treated with extra fluids.  Began 30 minutes after vaccine and lasted about 4 hours. 2.  Fatigue and lethargy.  Treated with rest and fluids.   Began 24 hours after vaccine. Duration 12 hours. 3.  Nasal congestion.   No treatment necessary.   Began 24 hours after vaccine.  Duration 4 days.
Hives; Rash; This spontaneous case was reported by an other health care professional and describes the occurrence of URTICARIA (Hives) and RASH (Rash) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced URTICARIA (Hives) and RASH (Rash). At the time of the report, URTICARIA (Hives) and RASH (Rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant were reported.  No treatment were reported.   Most recent FOLLOW-UP information incorporated above includes: On 17-Nov-2021: Follow up document received and included NewEvent information.
Arm pain after getting their first dose of the Moderna covid19; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Arm pain after getting their first dose of the Moderna covid19) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 0331521a) for COVID-19 vaccination.     Concurrent medical conditions included Hypercholesterolemia, Blood pressure and Diabetic. Concomitant products included ATORVASTATIN, LISINOPRIL and EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE (SYNJARDY) for an unknown indication.    On 10-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Jul-2021, the patient experienced PAIN IN EXTREMITY (Arm pain after getting their first dose of the Moderna covid19). At the time of the report, PAIN IN EXTREMITY (Arm pain after getting their first dose of the Moderna covid19) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment medication was not reported.  Reporter mentioned that patient stopped taking concomitant medications five days prior to vaccination and didn't specified the motive for this decision.   Most recent FOLLOW-UP information incorporated above includes: On 11-Jul-2021: Follow up received on 11-JUL-2021 is not significant. Event verbatim is changed but the PT term remains the same.
RLE dystonia started the day following the vaccines given. Undergoing further evaluation at this time.
Patient described body aches, chills and general unwell feeling beginning the evening after vaccination and lasting for about 3 days.  Patient self treated with OTC medications. Patient was covid positive last fall.
Five days after receiving the Covid-19 vaccine, patient suddenly began having trouble breathing. We called 911 right away but, by the time EMS arrived, she was unconscious and didn't appear to be breathing. Patient was not sick at the time this occurred but she was hospitalized in December of 2019 and was diagnosed with pulmonary fibrosis and pulmonary hypertension which required her to go home with and continue on supplemental oxygen. However, she never experienced pulmonary distress after coming home and her SPO2 levels consistently ranged between 96 and 99% with supplemental oxygen. Patient's death was very sudden and unexpected.
First two days:  slight dizziness, nausea, chills, sore arm - only lasting about 1/2 hour each day.   Evening of day two:  Headache started. and continues each day getting a little worse each day.  Took Ibuprofen-helped slightly Day five:  Bad headache all day and from previous night.  Contacted doctor through MY Chart.  He said persistent headaches with Pfizer vaccine were uncommon and suggested a treatment.. I declined as I had used that medication 30+years ago and didn't like it. Day six:  Better Day seven:  Better Day eight:  Still with headache, sinus drainage, chest pain (like I was coming down with a cold) Day nine:  No chest pain, drainage and headache, ringing in ears Day ten: More drainage and headache, ringing in ears
pt recvd vax; 30 min later devel abd cramps, shaking & anorexia